UBS Sets $60 Target for Scholar Rock; Analysis Predicts $97 Price on Apitegromab Data
UBS analyst Michael Yee set a $60 price target for SRRK on January 7, implying 45.24% upside from $41.31, and Barclays increased its 12-month target to $52 above the $48.90 consensus. A report raised SRRK’s target to $97, citing apitegromab’s Phase 3 data, manufacturing remediation and broad label potential.
1. Analyst Price Target Revisions
On January 7, 2026, Michael Yee of UBS increased his 12-month target for SRRK to $60, implying roughly 45% upside to current levels. This optimistic revision is supported by Barclays, which lifted its target from $45 to $52 while maintaining an "overweight" rating. Overall, the average analyst target sits at $48.90, reflecting broad confidence in the company’s near-term growth trajectory.
2. Broker Recommendations and Ratings
Among sixteen brokerages covering SRRK, eleven carry a "Buy" recommendation, four have issued "Strong Buy" ratings and one holds a "Sell" stance. Cantor Fitzgerald reiterated its "Overweight" rating on December 11, and Wolfe Research initiated coverage on November 18 with an "Outperform" rating and a $42 target. Despite a recent 3.39% pullback, the preponderance of bullish ratings underscores collective optimism around the firm’s late-stage clinical assets.
3. Trading Activity and Market Capitalization
In recent sessions, SRRK has fluctuated between intraday lows near $41.20 and highs around $43.10, following a 3.39% downward move from mid-December. Over the past year, the shares have ranged from approximately $22.70 to $48.30. The company’s market capitalization stands near $4.2 billion, with average daily trading volume exceeding 700,000 shares, signaling sustained investor interest in its pipeline developments.